key: cord-0863929-geadwh9v authors: Chung, Yoojin Lindsey; Rhie, Young-Jun title: Severe Obesity in Children and Adolescents: Metabolic Effects, Assessment, and Treatment date: 2021-12-30 journal: J Obes Metab Syndr DOI: 10.7570/jomes21063 sha: 602c01469a7925dc6fc72122621b2d66c8ccbe7e doc_id: 863929 cord_uid: geadwh9v Childhood obesity has been increasing steadily in recent decades, and severe childhood obesity has emerged as a major public health problem both nationally and internationally. A current concern is that lockdown due to the coronavirus disease 2019 (COVID-19) pandemic could exacerbate the spread of childhood obesity and increase the gap in obesity risk. Recent research results indicate the aggravation of obesity after school closures. The consequences of severe childhood obesity are more devastating than those of mild to moderate obesity. Children with severe obesity are at greater risk than others for hypertension, type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease, atherosclerosis, and adult obesity. Accurately assessing and diagnosing a child with severe obesity is the key to implementing successful therapy. A detailed and accurate patient history and physical examination are important to discriminate monogenic obesity and metabolic syndrome diagnoses from severe obesity without an underlying cause. Psychosocial factors, including eating behaviors, should be assessed to facilitate better weight management outcomes. Treatment options for severe pediatric obesity include lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery. However, lifestyle modification should be the priority. Although progress has been made, safe and effective treatment for severe pediatric obesity is still challenging. More efforts and innovations are needed to find a solution for the huge medical and emotional burden that these children and their families carry. Public health organizations also need to make efforts to encourage and normalize healthy eating habits and exercise to prevent severe obesity in childhood. The prevalence of pediatric obesity has increased dramatically during the past forty years in Korea and worldwide. 1, 2 Although recent data suggest that the increase in pediatric obesity has slowed and its overall prevalence has begun to stabilize, severe pediatric obesity continues to increase consistently. 3, 4 The overall prevalence of severe pediatric obesity in Korea increased from 1.2%-1.8% in 2001 to 2.1%-2.4% in 2013-2014. 4 The coronavirus disease 2019 pandemic is causing long-term school closures, which could be exacerbating the spread of childhood obesity and increas-childhood. [13] [14] [15] [16] Children with severe obesity have more adverse cardiometabolic risks than children who are overweight or have mild to moderate obesity. Early signs of vascular dysfunction and subclinical atherosclerosis have also been reported in children with severe obesity. [17] [18] [19] When adiposity was tracked from childhood into adulthood, the degree of retained adiposity was stronger in cases of severe childhood obesity. 20, 21 Therefore, preventing and treating severe pediatric obesity is important to prevent and attenuate the risk of preclinical atherosclerosis. 21 In this article, we focus on ways to assess pediatric patients with severe obesity and outline the main therapeutic approaches used to treat severe childhood obesity: lifestyle modification therapy, pharmacotherapy, and metabolic and bariatric surgery (MBS). Most adult obesity begins in childhood, 22, 23 making pediatric obesity a concern and giving impetus to medical professionals to prevent and treat childhood obesity. Body mass index (BMI) is the acknowledged indicator of obesity in both children and adults. 24 Using normal BMI curves for age and sex in children, a BMI at or above the 85th percentile and below the 95th percentile is categorized as overweight, and a BMI at or above the 95th percentile is categorized as obesity. Obesity is further divided into three classes by using the 95th percentile for age and sex as the reference value and categorizing 100% to 120% of the 95th percentile as class I obesity, 120% to 140% as class II obesity, and more than 140% as class III obesity (Table 1) . 3, 25, 26 Severe pediatric obesity is defined as class II and III obesity. Cardiometabolic risk increases with rising degrees of obesity, and class II and III obesity have a strong association with these risks. 25 In pediatric obesity, metabolic and cardiovascular complications are observed during childhood and are closely related to the development of insulin resistance, which is the most widely recognized biochemical change in obesity. 27 The comorbidities related to obe-sity from early childhood are glucose intolerance, dyslipidemia, and hypertension. The cluster of these medical conditions is called metabolic syndrome, or insulin resistance syndrome, and includes T2DM, hypertension, dyslipidemia, and coronary heart disease. 28 Insulin resistance is defined as a decreased tissue response to insulin-mediated cellular actions and is the inverse of insulin sensitivity. The insulin resistance seen in obesity does not affect all tissues equally because insulin affects the liver, adipose tissues, and muscle in different ways. Insulin in the liver diminishes hepatic glucose production and increases the transcription of genes required for fatty acid and triglyceride biosynthesis. Insulin-resistant subjects can have selective hepatic insulin resistance, which is impaired glucose homeostasis but normal insulin-mediated hepatic de novo lipogenesis. 29, 30 The resulting increase in free fatty acid (FFA) flux within the liver impairs hepatic insulin action via fatty acyl-CoA intermediates within hepatocytes, 31 which increases hepatic glucose output, the synthesis of proinflammatory cytokines, and triglyceride secretion by the liver; lowers high-density lipoprotein cholesterol levels; and increases relatively cholesterol-depleted lowdensity lipoprotein particles. 32 Furthermore, the intrahepatic accumulation of FFA and lipids is itself detrimental to liver insulin sensitivity. 33 Intrahepatic insulin resistance results in greater first-pass insulin clearance in the liver, which lowers the amount of insulin reaching systemic circulation. The expanded adipose tissue mass that accompanies obesity leads to increased lipolysis and FFA turnover. Insulin resistance accelerates the lipolytic process, leading to increased FFA release into the circulation. Moreover, visceral adipocytes are more sensitive to catecholamine-stimulated lipolysis than subcutaneous adipocytes, which further increases FFA release. 34 A greater FFA concentration following an oral glucose load worsens glucose tolerance. 35 Increased plasma FFA flux into skeletal muscle results in fatty acyl-CoA derivatives that alter the insulin signal transduction pathway and reduce insulin-mediated glucose trans- 33 Intramyocellular lipid deposition is tightly associated with insulin resistance and has been detected in children with obesity who have altered glucose metabolism. 36, 37 The risk of the metabolic syndrome is higher in teenage boys with severe obesity than girls, as shown by a Korean population study, which found that the rates of metabolic syndrome in obese teenage boys were more than double those in girls, which is consistent with a prior study from the United States. 4,25 When an accurate diagnosis is made and complications are properly identified, severe pediatric obesity can be treated successfully. A thorough medical history from birth to the present should be taken, including birth weight, BMI of both parents, exposure to gestational diabetes, maternal obesity, prematurity, history of breastfeeding, neonatal complications, neurodevelopmental abnormalities, signs of dysmorphism, and medication use, especially glucocorticoids, antiepileptics, and antipsychotics. Orthopedic problems, headaches, and snoring must also be assessed. It is very important to identify the potential underlying contributors to metabolic dysregulation because obesity is a heterogeneous disease. 38 In a physical examination, linear growth gives clues that can be used to exclude organic causes of obesity; however, hyperinsulinemia and insulin resistance can cause accelerated growth through crossreactivity between insulin and the insulin-like growth factor 1 receptor. 39 Acanthosis nigricans and waist circumference are important physical features because both clinical characteristics are correlated with insulin resistance and metabolic syndrome. A laboratory evaluation should be conducted and assessed for obesity-related comorbidity markers, including aspartate aminotransferase, alanine aminotransferase, lipids, fasting glucose, and hemoglobin A1c. Luteinizing hormone, follicular-stimulating hormone, and testosterone levels should be examined to evaluate delayed puberty in boys and PCOS in girls. 40 An oral glucose tolerance test for T2DM could be necessary when familial risk factors are present. 40 Genetics is the greatest contributor to obesity, and 30%-90% of genetic variation in BMI is heritable. 41 Simple obesity arises through the additive effects of multiple genes associated with obesity. 42 On the other hand, 5% to 10% of children with hyperphagia and obesity in early childhood have a monogenic condition that causes obesity; most of those cases arise from monogenic disorders of the leptin-melanocortin pathway. 43 Therefore, patients with severe obesity or obesity in early childhood who also have developmental delay, dysmorphic features, short stature, or intellectual disability require a genetic evaluation. The identification of monogenic obesity could help to identify pharmacological treatments, such as setmelanotide, a melanocortin-4 receptor agonist for proopiomelanocortin, or proprotein convertase subtilisin/kexin type 1 or leptin, a hormone related to satiety, for leptin receptor deficiency, 44 and direct further evaluations for other comorbidities, including organ-specific anomalies. Other biological factors, including endocrine disorders such as growth hormone deficiency, hypothyroidism, and Cushing syndrome, should also be evaluated. Eating behaviors are an additional determining factor of obesity. In addition to the typical assessment of dietary components, such as the frequency of fast food or sugar-sweetened beverage con- Obese children, especially those looking for obesity treatment, have a greater tendency than normal-weight children to have psychological problems such as depression, anxiety, attention deficit hyperactive disorder (ADHD), and eating disorders. 48 The incidence of depression is three times higher and anxiety is five times higher in adolescents with severe obesity than in those with moderate obesity. 49 The prevalence of binge eating is reported to be higher in children with severe obesity (17%) than mild to moderate obesity (10%). 50 showed that a high BMI was a negative predictor for quality of life. 51 In a study of 361 youth looking for a weight loss program, the rate of weight-based victimization increased with body weight. 52 Identifying when children are experiencing victimization and providing the needed support or resources in school and at home is an essential part of any obesity management plan. Lifestyle modification therapy is essential for pediatric obesity treatment. Especially for children with severe obesity, it should be used as the first-line therapeutic option. 26 Meal replacement therapy is a form of low-calorie diet in which one or two full-calorie meals daily are replaced with low-calorie frozen meals, shakes, or bars. It has been used with short-term success in adolescents with severe obesity. 56 These kinds of meals provide convenient portion control; however, weight regain began at the finish of therapy when a normal diet was resumed. In addition, longterm compliance is poor, and using this therapy in children might be limited by poor acceptance among both parents and patients. Physical activity is the second most important behavioral intervention. The American Academy of Pediatrics and European Society for Pediatric Endocrinology recommend physical activity regardless of weight status, encouraging daily moderate-to-vigorous physical activity and limiting screen time to 1 to 2 hours a day. 57, 58 Most children, including children with severe obesity, do not achieve those recommendations. Exercise physiologists and physical therapists can help children by developing individual exercise plans, especially when movement is limited by gross motor delays or musculoskeletal pain. 59 However, although interest in the application of physical therapy to severe obesity is increasing, many program developments are needed to apply it within the current medical system. The primary treatment option for pediatric obesity is lifestyle modification therapy. Pharmacotherapy is the next logical treatment for patients who fail to meet their weight loss goals with lifestyle modification therapy alone ( [73] [74] [75] [76] In addition, studies of MBS in rare pediatric cases with genetic defects as the primary cause of severe obesity (Prader-Willi syndrome and melanocortin 4 receptor mutation) have shown promising BMI reduction and resolution of comorbidities. 77, 78 MBS has the potential to cause both macro-and micronutrient deficiency, and lifelong supplementation of protein, iron, calcium, and vitamins is required to prevent deficiencies. Because RYGB uses both restrictive and malabsorptive mechanisms for weight reduction, deficiencies are more likely to occur than in VSG. 72 Another complication of MBS is gastro-esophageal reflux, which occurs more frequently with laparoscopic VSG than RYGB; 12%-30% of patients require long-term use of proton pump inhibitors. 79 All of these surgical procedures put patients at risk for leakage at the anastomosis site, hernia, stricture, and wound infection; however, those complications occur less frequently in pediatric patients than in adult patients. 79 The number of children and adolescents with severe obesity in Korea has increased substantially; because its short-and long-term health consequences are unavoidable, severe pediatric obesity should be treated comprehensively. Furthermore, because accumulating evidence suggests that severe obesity in childhood is usually associated with adverse metabolic profiles, early screening for obesity-related comorbidities such as diabetes or hypertension should be recommended. By using early-life weight-gain trajectory data to differentiate young children who are at risk of developing severe obesity, clinicians could intervene early to reduce metabolic risk in adulthood. Family-based interventions in early life could be effective solutions to prevent severe pediatric obesity. The treatment options for children who have severe obesity include lifestyle modification therapy, pharmacological therapy, and bariatric surgery, but innovative therapies with progressively more intensive methods need to be developed and evaluated to improve outcomes for children afflicted with this disease. To make meaningful progress, health professionals who treat pediatric obesity need to be aware of the causes and biological significance of severe obesity, and further research evaluating intensive treatment approaches is urgently needed. Also, those health professionals and public health officials must incorporate their area of expertise into public health programs and policies for childhood obesity to foster a community-based approach and develop and maintain obesity prevention programs for children and adolescents. The authors declare no conflict of interest. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 populationbased measurement studies in 128ยท9 million children, adolescents, and adults Secular trends in pediatric overweight and obesity in Korea Prevalence of obesity and severe obesity in US children Trends in the prevalence of extreme obesity among Korean children and adolescents from 2001 to 2014 COVID-19-related school closings and risk of weight gain among children The impact of the coronavirus disease-2019 pandemic on childhood obesity and vitamin D status COVID-19-related school closing aggravate obesity and glucose intolerance in pediatric patients with obesity Impact of the COVID-19 pandemic on seasonal variations in childhood and adolescent growth: experience of pediatric endocrine clinics Socioeconomic status and obesity Socioeconomic status and adiposity in childhood: a systematic review of cross-sectional studies The association between socioeconomic status and obesity in Korean children: an analysis of the Fifth Korea National Health and Nutrition Examination Survey The associations between socioeconomic status and obesity in Korean children from Body mass index and incident type 1 and type 2 diabetes in children and young adults: a retrospective cohort study Severe Obesity in Children and Adolescents NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASP-GHAN) Obesity, hypertension, and dyslipidemia in childhood are key modifiable antecedents of adult cardiovascular disease: a call to action Hypertension in childhood obesity Prevalence of metabolic syndrome (MS) in children and adolescents with varying degrees of obesity Hassink S. Severe obesity associated with cardiovascular deconditioning, high prevalence of cardiovascular risk factors, diabetes mellitus/hyperinsulinemia, and respiratory compromise Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study Distinct child-to-adult body mass index trajectories are associated with different levels of adult cardiometabolic risk Johnson CL. Overweight prevalence and trends for children and adolescents: the National Health and Nutrition Examination Surveys Predicting obesity in young adulthood from childhood and parental obesity Use of the body mass index (BMI) as a measure of overweight in children and adolescents Cardiometabolic risks and severity of obesity in children and young adults Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study Pathophysiology of insulin resistance in human disease Selective versus total insulin resistance: a pathogenic paradox The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes Nocturnal free fatty acids are uniquely elevated in the longitudinal development of diet-induced insulin resistance and hyperinsulinemia Regulation of plasma triglycerides in insulin resistance and diabetes The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia Adipose insulin resistance in obese adolescents across the Severe Obesity in Children and Adolescents spectrum of glucose tolerance Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning Obesity is a sign: over-eating is a symptom. An aetiological framework for the assessment and management of obesity Expression of the components of the insulin-like growth factor axis across the growth-plate Obesity, metabolic syndrome and disorders of energy balance Variation in the heritability of body mass index based on diverse twin studies: a systematic review Genetics of severe obesity Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals Eating behaviours are different in youth with obesity and severe obesity Sleep-obesity relation: underlying mechanisms and consequences for treatment Does stress influence sleep patterns, food intake, weight gain, abdominal obesity and weight loss interventions and vice versa? Psychological correlates of childhood obesity Depression, anxiety, and severity of obesity in adolescents: is emotional eating the link? Socioenvironmental, personal, and behavioral correlates of severe obesity among an ethnically/racially diverse sample of US adolescents Severe obesity and comorbid condition impact on the weight-related quality of life of the adolescent patient Weight-based victimization: bullying experiences of weight loss treatment-seeking youth Response of severely obese children and adolescents to behavioral treatment Efficacy and safety of low-carbohydrate diets: a systematic review Recent advances in the treatment of childhood obesity Meal replacements in the treatment of adolescent obesity: a randomized controlled trial Council on Sports Medicine and Fitness; Section on Obesity. Physical activity assessment and counseling in pediatric clinical settings Pediatric obesity-assessment, treatment, and prevention: an Endocrine Society clinical practice guideline Severe Obesity in Children and Adolescents Evaluation and treatment of severe obesity in childhood Clinical considerations regarding the use of obesity pharmacotherapy in adolescents with obesity Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents Effect of phentermine on weight reduction in a pediatric weight management clinic Efficacy and safety of metformin for obesity: a systematic review Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US Preventive Services Task Force Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial A 6-month randomized, doubleblind, placebo-controlled trial of weekly exenatide in adolescents with obesity A randomized, controlled trial of liraglutide for adolescents with obesity GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases Successful rapid weight reduction and the use of liraglutide for morbid obesity in adolescent Prader-Willi syndrome ASMBS pediatric metabolic and bariatric surgery guidelines Weight loss and health status 3 years after bariatric surgery in adolescents Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a prospective follow-up analysis Laparoscopic Roux-en-Y gastric bypass in adolescents with severe obesity (AMOS): a prospective, 5-year, Swedish nationwide study Factors associated with long-term weight-loss maintenance following bariatric surgery in adolescents with severe obesity Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched control study Weight loss after bariatric surgery in morbidly obese adolescents with MC4R mutations Bariatric surgery for severely overweight adolescents: concerns and recommendations Study concept and design: all authors; drafting of the manuscript: YLC; critical revision of the manuscript: all authors; study supervision: YJR.